Nuclera and University of Cambridge researchers demonstrate rapid structural analysis of challenging drug target

Collaboration combines cell-free protein synthesis, proprietary nanodisc technology and cryo-electron microscopy (cryo-EM) for high-resolution structural analysis of a G protein-coupled receptor (GPCR)

Nuclera, the biotechnology company enabling access to innovative protein technologies, has announced the publication of research with the University of Cambridge's Department of Biochemistry.

The study demonstrates a rapid, cell-free approach using proprietary nanodisc technology to produce challenging drug-target proteins for high-resolution structural analysis.

Nuclera and University of Cambridge researchers demonstrate rapid structural analysis of challenging drug target

The research, published as a bioRxiv preprint, reports a 3.38 Å cryo-EM structure of an engineered human adenosine A2A receptor (A2AR) bound to an antagonist, with the workflow from gene assembly to cryo-EM sample preparation completed in 4 days.

The findings show potential to overcome a longstanding bottleneck in structural biology, speeding access to difficult-to-express proteins and supporting structure-based drug discovery.

GPCRs are a major class of therapeutic targets. Despite advances in cryo-EM, obtaining sufficient quantities of stable, correctly folded GPCRs remains a bottleneck, as conventional production often requires extensive optimisation.

Researchers combined Nuclera's protein discovery system with Cambridge's cryo-EM expertise

Using cell-free synthesis, they screened A2AR constructs against six lipid nanodisc conditions from Nuclera's GPCR nanodisc panel.


One of the highest-yielding conditions was scaled up for purification, quality assessment and cryo-EM analysis, enabling high-resolution analysis of the antagonist-bound A2AR, whose architecture closely matched a conventionally produced reference.


To test wider applicability, the researchers also produced and purified 12 further GPCRs across Classes A, B and C, including six orphan receptors with no identified endogenous ligands.

Nuclera and University of Cambridge researchers demonstrate rapid structural analysis of challenging drug target

Assessed by fluorescence-detection size-exclusion chromatography (FSEC), they show the workflow could be applied across diverse GPCR targets, supporting further structural and biophysical studies.

Dr Dimitri Chirgadze (pictured), Cryo-EM Facility Manager, Department of Biochemistry, University of Cambridge, said: "Cryo-EM has transformed our ability to investigate protein structures, but obtaining suitable samples remains a major challenge, particularly for complex membrane proteins."

"This research shows rapid, cell-free production can deliver high-quality, active protein for high-resolution analysis, potentially opening up a wider range of challenging drug targets."

Dr Michael Chen, founder and Chief Scientific and Business Officer at Nuclera, commented: "Access to membrane proteins remains a significant obstacle in drug discovery."

"By combining our cell-free synthesis and nanodisc technology with Cambridge's structural biology expertise, we have shown a faster route to proteins suitable for high-resolution analysis."

"This is an important step towards making difficult-to-study drug targets more accessible, accelerating structural biology research and streamlining drug discovery."

Trending Articles

You may also like